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ing or is it only engaged in protein-protein 
interactions? Is the increase in Ars2 lev-
els observed during the transition from 
cell quiescence to proliferation reflected 
in expression of miRNAs dependent on 
Ars2 for correct processing? And if so, 
what sequence or structure motif causes 
these miRNAs to be responsive to Ars2? 
Finally, given the small number of genes 
screened for involvement in viral resis-
tance, how many other regulatory com-
ponents are still waiting to be identified? 
With a growing understanding of the 
mechanisms behind small RNA path-
ways the new challenge in RNA biology is 
to understand how the silencing machin-
ery is interconnected with general RNA 
metabolism. We have certainly not seen 
the last canonical RNA metabolic factor 
crossing over into the miRNA field.
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1503–1514.The cancer stem cell hypothesis postu-
lates that the progeny of a small pluripo-
tent population of malignant stem cells 
makes up the bulk of a malignant tumor. 
Among cancers, acute myeloid leukemia 
(AML) has the most clearly defined popu-
lation of stem cells—known as leukemic 
stem cells (LSCs)—that is responsible for 
AML persistence and relapse. Therefore, 
there is considerable interest in identify-
ing therapies that specifically target this 
particular population of cells. Leukemic 
stem cells and their normal counterpart, 
the hematopoietic stem cells (HSCs), 
show remarkable resilience to the direct 
cytotoxic and indirect inflammatory 
effects of chemotherapy. This results, in 
part, from their ability to circulate freely 
in the peripheral blood and repopulate 
the bone marrow stem cell niche while 
avoiding phagocytosis by activated 
macrophages (Figure 1). In this issue of 
Cell, Jaiswal et al. (2009) and Majeti et al. 
(2009) show that the immunoglobulin-like 
protein CD47 expressed by LSCs acts as 
an inhibitor of macrophage activity and 
directly promotes enhanced survival and 
engraftment of LSCs (Figure 1). Further-
more, they demonstrate that high levels 
of CD47 on LSCs isolated from patients 
with AML are predictive of leukemia 
resistance to therapy, possibly reflecting 
the ability of LSCs to avoid macrophage-
mediated control.
CD47 is a membrane protein that 
functions in neutrophil trafficking, T cell 
costimulation, and neuronal regenera-
tion (Matozaki et al., 2009). CD47 also 
interacts with a specific macrophage 
receptor, SIRPα, to downregulate the 
phagocytic potential of macrophages 
(van den Berg and van der Schoot, 
2008). Given that mobilized HSCs in the 
blood stream come into contact with 
macrophages of the reticulo-endothelial 
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Expression of the cell-surface protein CD47 allows some normal cells to avoid phagocytosis by 
macrophages. In this issue, Jaiswal et al. (2009) and Majeti et al. (2009) show that elevated CD47 
expression by leukemic stem cells inhibits macrophage activity and is an indicator of poor prog-
nosis for patients with acute myeloid leukemia.226 Cell 138, July 24, 2009 ©2009 Elsevier Inc.
figure 1. cD47 in Hematopoietic stem cells and Leukemic stem cells
The expression of CD47 by normal hematopoietic stem cells (HSC) varies depending on the physiological context. The CD47 receptor SIRPα is expressed by 
macrophages and interacts with HSC CD47 in settings of homeostatic maintenance, inflammation/sepsis, and possibly HSC senescence with differing out-
comes. Similarly, leukemic stem cells (LSC) in acute myeloid leukemia (AML) interact with macrophages and express different levels of CD47 in different clinical 
settings. The level of CD47 expression correlates with the prognosis of AML patients, with lower CD47 expression found in those with a good prognosis (for 
example, harboring the cytogenetic marker t(8;21)) and higher CD47 expression found in those with a poor prognosis (for example, marked by FLT3-ITD expres-
sion). The treatment of patients with antibodies against CD47 that block its interaction with SIRPα may alter the clinical outcome by promoting phagocytosis 
and clearance of LSCs.system (in the spleen and bone marrow) 
but escape phagocytosis, it is possible 
that survival of normal HSCs is at least 
partially dependent on their upregulation 
of CD47 expression (Figure 1).
Jaiswal and colleagues explore the 
expression of CD47 on normal HSCs 
mobilized after chemotherapy by granu-
locyte-colony stimulating factor (G-CSF) 
or the endotoxin lipopolysaccharide 
(LPS). They hypothesize that upregula-
tion of CD47 expression is necessary 
for HSC survival in the G-CSF or LPS-
induced inflammatory environment 
where there is increased macrophage 
phagocytic activity. Indeed, they find 
that HSCs expressing only one copy of 
the CD47 gene are more poorly trans-
planted in comparison to HSCs express-
ing both copies of the CD47 gene. This 
decreased transplantation fitness is due 
to increased clearance of the stem cells 
by macrophages. As normal HSCs have much in common with myeloid LSCs, 
Jaiswal et al. also examine the expres-
sion of CD47 on isolated populations 
of LSCs. Beyond confirming an earlier 
report of increased expression of CD47 
in leukemic bone marrow (Traver et al., 
1998), the authors find that cells from an 
isolated putative myeloid LSC popula-
tion have increased expression of CD47 
relative to normal HSCs. This suggests 
that LSCs are likely to enjoy enhanced 
survival due to decreased clearance by 
macrophages (Figure 1). LSCs isolated 
from a range of myeloid malignancies 
in patients also display elevated CD47 
expression. Strikingly, those patients 
with the most malignant myeloprolifera-
tive disorders (chronic myeloid leukemia 
in blast crisis and AML) uniformly dem-
onstrate the highest expression of CD47. 
Other myeloid proliferative disorders that 
do not have an expanded malignant stem 
cell population (including polycythemia, Celmyelofibrosis, and essential thromboth-
ycemia) did not show increased CD47 
expression in their stem cell populations. 
These clinical data and other experimen-
tal data presented in the studies suggest 
that CD47 is not simply a differentiation 
marker. Instead, they strongly implicate 
increased CD47 expression as an attri-
bute of the highly malignant LSC popu-
lations found in chronic myeloid leuke-
mia in blast crisis and AML, suggesting 
that elevated levels of CD47 expression 
could underlie the rapid clinical course 
and incurability of the majority of these 
patients.
In light of the findings of Jaiswal et al., 
an obvious hypothesis is that in clinical 
presentations of AML, high expression 
of CD47 should result in the increased 
“escape” of LSC populations from mac-
rophage-mediated surveillance. Indeed, 
Majeti et al. make this observation when 
examining LSCs from AML patients l 138, July 24, 2009 ©2009 Elsevier Inc. 227
where the disease was refractory to or 
relapsed shortly after remission induc-
tion chemotherapy. Currently, AML 
prognosis is best determined by cyto-
genetic analysis of leukemic blasts (Byrd 
et al., 2002). In cases where this is nor-
mal, the next step is to look for the pres-
ence of molecular abnormalities such as 
the expression of fms-related tyrosine 
kinase 3-internal tandem repeats (FLT3-
ITD) (which confers a poor prognosis) or 
nucleophosmin-1 (which confers a bet-
ter prognosis in the absence of FLT3-ITD 
expression) (Schlenk et al., 2008). Using 
well-documented criteria for stem cell 
identification, Majeti et al. report that 
the predictive value of CD47 expression 
in the LSC population is independent 
of most known prognostic indicators. 
An important exception to this is the 
AML subgroup harboring the cytoge-
netic abnormality t(8;21) (a chromosomal 
translocation between chromosome 8 
and 21), which is associated with a better 
prognosis (Figure 1). The AML subgroup 
expressing the poor prognosis molecu-
lar marker FLT3-ITD is also an exception 
and shows the highest levels of CD47 
expression (Figure 1).
Majeti et al. find that AML patients can 
be stratified into distinct groups based 
on CD47 expression. Survival (both dis-
ease-free and overall) is markedly longer 
in patients expressing low levels of CD47. 
This association also remains significant 
in a multivariate analysis of age, FLT3-ITD 
status, and CD47 expression, providing a 
clinical context to the in vitro and animal 
model studies of Jaiswal et al. Majeti and 
colleagues further show that consistent 
with findings in mice, CD47 expression 
on human LSCs results in decreased 
phagocytosis by macrophages, an effect 
that can be reversed by the presence of 
antibodies directed against CD47 (Fig-
ure 1) or SIRPα (the CD47 receptor on 
macrophages). Notably, normal HSCs 
treated with antibodies against CD47 did 
not seem susceptible to macrophage-
mediated phagocytosis, indicating that 
inhibition of the CD47-SIRPα interac-228 Cell 138, July 24, 2009 ©2009 Elsevier Ition is insufficient to induce phagocyto-
sis of healthy HSCs. This suggests that 
another signal for engulfment exists on 
LSCs, “pre-priming” them for phagocy-
tosis when CD47 cannot interact with 
SIRPα. Given that the in vivo viability 
of healthy HSCs is not impaired when 
CD47 is blocked by a monoclonal anti-
body, it may be possible to promote the 
clearance of LSCs without any detriment 
to bone marrow repopulation by normal 
HSCs. Thus, the authors provide the first 
glimpses of how a prosurvival signal for 
LSCs may be clinically subverted as a 
potential therapeutic target for leukemia 
(Figure 1).
Some questions remain unanswered 
by the studies of Jasiwal et al. and Majeti 
et al. For example, what is the normal 
physiological function of the interaction 
between normal HSCs and bone mar-
row or splenic macrophages? Could 
the interactions between bone mar-
row macrophages and HSCs express-
ing physiological levels of SIRPα and 
CD47, respectively, contribute to the HSC 
niche? Perhaps the expression of CD47 
is a surrogate marker of HSC physical fit-
ness that wanes as the HSC ages so that 
cells beyond an “expiration date” can be 
disposed of by tissue macrophages in 
a manner analogous to the clearance of 
damaged and senescent erythrocytes in 
the spleen. Bone marrow macrophages 
may, therefore, perform a normal homeo-
static function by providing macrophage-
derived survival signals to HSCs via the 
interaction between CD47 and SIRPα and 
may only switch to phagocytosis when 
CD47 expression drops below a certain 
level. The high expression of CD47 by 
malignant LSCs may represent another 
example by which prosurvival signals are 
hijacked by a malignant process to avoid 
normal immunosurveillance. Although 
little is known regarding host immuno-
surveillance of primitive pluripotent tumor 
stem cell populations, it has been pro-
posed that the immune system may selec-
tively “edit” the malignant cell population 
by destroying more susceptible cells, nc.thereby producing a pool of malignant 
cells that are resistant to immunological 
recognition and clearance (Swann and 
Smyth, 2007). Patients who harbor LSCs 
with high expression of CD47 may have 
already undergone this process in which 
their low (and potentially less malignant) 
LSCs have been cleared by endogenous 
macrophages, leaving the more resis-
tant LSCs that are ultimately responsible 
for poor clinical outcomes. A syngeneic 
mouse model of AML, where the role of 
CD47 and the safety of a neutralizing anti-
body can be fully explored, should dove-
tail with further clinical observations and 
trials to extend the major advances made 
by these two studies. These discoveries 
provide tangible avenues for the applica-
tion of new therapies that will enhance the 
clearance of LSCs in vivo and ultimately 
lead to improved patient outcomes in leu-
kemia.
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